Gene alterations by peroxisome proliferator-activated receptor γ agonists in human colorectal cancer cells

International Journal of Oncology

Volumn 32, Issue 4, 2008, Pages 809-819

  Cekanova, Maria ^a   Yuan, Joshua S ^b   Li, Xiuoon ^a   Kim, Kyubo ^a   Baek, Seung Joon ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Colon cancer; MCC 555; Micro array; PPAR; Rosiglitazone

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; BINDING PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 3; CYTOCHROME C OXIDASE; CYTOCHROME C OXIDASE 17; CYTOCHROME C OXIDASE 7A2; DIFFERENTIATION ASSOCIATED PROTEIN CYSTATIN A; DROSOPHILA PROTEIN; KELCH LIKE 11 PROTEIN; MAGO NASHI HOMOLOG PROTEIN; METALLOTHIONEIN I; METALLOTHIONEIN IJ; NETOGLITAZONE; NUCLEAR RECEPTOR COACTIVATOR 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN DERIVATIVE; PROTEIN L37A; PROTEIN S21; RAS INDUCED SENESCENCE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE 1ALPHA; RIBOSOME PROTEIN; ROSIGLITAZONE; STEFIN A; TATA BINDING PROTEIN ASSOCIATED FACTOR; TATA BINDING PROTEIN ASSOCIATED FACTOR 12; UBIQUINOL CYTOCHROME C REDUCTASE; 15 DEOXYPROSTAGLANDIN J2; 15-DEOXYPROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; DRUG DERIVATIVE; PROSTAGLANDIN D2;

ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL PROLIFERATION; COLON CARCINOGENESIS; COLORECTAL CARCINOMA; COMPUTER PROGRAM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE REPRESSION; HUMAN; HUMAN CELL; METABOLISM; MICROARRAY ANALYSIS; PLEIOTROPY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION; CELL STRAIN HCT116; COLORECTAL TUMOR; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION PROFILING; GENETICS; PHYSIOLOGY; TRANSACTIVATION;

COLORECTAL NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; PPAR GAMMA; PROSTAGLANDIN D2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TRANS-ACTIVATION (GENETICS);

EID: 44449152670     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Wang T, Xu J, Yu X, Yang R and Han ZC: Peroxisome proliferator-activated receptor gamma in malignant diseases. Crit Rev Oncol Hematol 58: 1-14, 2006.
2. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, et al: Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss and regulation by insulin and glucocorticoids. J Clin Invest 99: 2416-2422, 1997.
3. Bren-Mattison Y, van Putten V, Chan D, Winn R, Geraci MW and Nemenoff RA: Peroxisome proliferator-activated receptor-gamma [PPAR(gamma)] inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene 24: 1412-1422, 2005.
4. Vignati S, Albertini V, Rinaldi A, et al: Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. Neoplasia 8: 851-861, 2006.
5. Elstner E, Muller C, Koshizuka K, et al: Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95: 8806-8811, 1998.
6. Sarraf P, Mueller E, Jones D, et al: Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4: 1046-1052, 1998.
7. Konopleva M, Elstner E, McQueen TJ, et al: Peroxisome proliferator-activated. receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther 3: 1249-1262, 2004.
8. Baek SJ, Wilson LC, Hsi LC and Eling TE: Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. J Biol Chem 278: 5845-5853, 2003.
9. Bull AW: The role of peroxisome proliferator-activated receptor gamma in colon cancer and inflammatory bowel disease. Arch Pathol Lab Med 127: 1121-1123, 2003.
10. Okura T, Nakamura M, Takata Y, Watanabe S, Kitami Y and Hiwada K: Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. Eur J Pharmacol 407: 227-235, 2000.
11. Wang M, Wise SC, Leff T and Su TZ: Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-gamma. Diabetes 48: 254-260, 1999.
12. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM and Halperin JA: Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res 61: 6213-6218, 2001.
13. Davies GF, Khandelwal RL, Wu L, Juurlink BH and Roesler WJ: Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferator-activated receptor-gamma (PPARgamma)-independent, antioxidant-related mechanism. Biochem Pharmacol 62: 1071-1079, 2001.
14. Nikitakis NG, Siavash H, Hebert C, Reynolds MA, Hamburger AW and Sauk JJ: 15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells. Br J Cancer 87: 1396-1403, 2002.
15. Eligini S, Banfi C, Brambilla M, et al: 15-deoxy-delta12,14-Prostaglandin J2 inhibits tissue factor expression in human macrophages and endothelial cells: evidence for ERK1/2 signaling pathway blockade. Thromb Haemost 88: 524-532, 2002.
16. Yamaguchi K, Lee SH, Eling TE and Baek SJ: A novel peroxisome proliferator-activated receptor gamma ligand, MCC-555, induces apoptosis via posttranscriptional regulation of NAG-1 in colorectal cancer cells. Mol Cancer Ther 5: 1352-1361, 2006.
17. Yuan JS, Reed A, Chen F and Stewart CN Jr: Statistical analysis of real-time PCR data. BMC Bioinformatics 7: 85, 2006.
18. Nixon JB, Kamitani H, Baek SJ and Eling TE: Evaluation of eicosanoids and NSAIDs as PPARgamma ligands in colorectal carcinoma cells. Prostaglandins Leukot Essent Fatty Acids 68: 323-330, 2003.
19. Keppler D: Towards novel anti-cancer strategies based on cystatin function. Cancer Lett 235: 159-176, 2006.
20. Kos J and Lab TT: Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review). Oncol Rep 5: 1349-1361, 1998.
21. Strojan P, Budilma M, Smid L, et al: Prognostic significance of cysteine proteinases cathepsins B and L and their endogenous inhibitors stefins A and B in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 6: 1052-1062, 2000.
22. Yeh CT, Lu SC, Chao CH and Chao ML: Abolishment of the interaction between cyclin-dependent kinase 2 and Cdk-associated protein phosphatase by a truncated KAP mutant. Biochem Biophys Res Commun 305: 311-314, 2003.
23. Zhao XF, Colaizzo-Anas T, Nowak NJ, Shows TB, Elliott RW and Aplan PD: The mammalian homologue of mago-nashi encodes a serum-inducible protein. Genomics 47: 319-322, 1998.
24. Boswell RE, Prout ME and Steichen JC: Mutations in a newly identified Drosophila melanogaster gene, mago-nashi, disrupt germ cell formation and result in the formation of mirror-image symmetrical double abdomen embryos. Development 113: 373-384, 1991.
25. Skehel JM, Fearnley IM and Walker JE: NADH: ubiquinone oxidoreductase from bovine heart mitochondria: sequence of a novel 17.2-kDa subunit. FEBS Lett 438: 301-305, 1998.
26. Barradas M, Gonos ES, Zebedee Z, et al: Identification of a candidate tumor-suppressor gene specifically activated during Ras-induced senescence. Exp Cell Res 273: 127-137, 2002.
27. Kok K, Naylor SL and Buys CH: Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Adv Cancer Res 71: 27-92, 1997.
28. Iglesias D, Fernandez-Peralta AM, Nejda N, et al: RIS1, a gene with trinucleotide repeats, is a target in the mutator pathway of colorectal carcinogenesis. Cancer Genet Cytogenet 167: 138-144, 2006.
29. Martinez E: Multi-protein complexes in eukaryotic gene transcription. Plant Mol Biol 50: 925-947, 2002.
30. Hamard PJ, Dalbies-Tran R, Hauss C, Davidson I, Kedinger C and Chatton B: A functional interaction between ATF7 and TAF12 that is modulated by TAF4. Oncogene 24: 3472-3483, 2005.
31. Wu YL and Gong Z: A novel zebrafish kelchlike gene klhl and its human ortholog KLHL display conserved expression patterns in skeletal and cardiac muscles. Gene 338: 75-83, 2004.
32. Powell SM, Christiaens V, Voulgaraki D, Waxman J, Claessens F and Bevan CL: Mechanisms of androgen receptor signalling via steroid receptor coactivator-1 in prostate. Endocr Relat Cancer 11: 117-130, 2004.